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Abstract Insight into risks of nanotechnology and
the use of nanoparticles is an essential condition for the
social acceptance and safe use of nanotechnology. One
of the problems with which the risk assessment of
nanoparticles is faced is the lack of data, resulting in
uncertainty in the risk assessment. We attempt to
quantify some of this uncertainty by expanding a
previous deterministic study on nanosilica (5–200 nm)
in food into a fully integrated probabilistic risk
assessment. We use the integrated probabilistic risk
assessment method in which statistical distributions
and bootstrap methods are used to quantify uncertainty
and variability in the risk assessment. Due to the large
amount of uncertainty present, this probabilistic
method, which separates variability from uncertainty,
contributed to a better understandable risk assessment.
We found that quantifying the uncertainties did not
increase the perceived risk relative to the outcome of
the deterministic study. We pinpointed particular
aspects of the hazard characterization that contributed
most to the total uncertainty in the risk assessment,
suggesting that further research would benefit most
from obtaining more reliable data on those aspects.
Keywords Dose metric  E551  Margin of
exposure  Uncertainty  Variability 
Nanotechnology  Governance
Introduction
Insight into risks of nanotechnology and the use of
nanoparticles is an essential condition for the social
acceptance and safe use of nanotechnology. Many
frameworks have been developed for risk assessment
of nanomaterials, as were summarized by Grieger et al.
(2012). These include frameworks for risk governance,
risk screening, adaptable risk assessment tools, and
risk assessment and management frameworks. The
majority of the frameworks were developed for
environmental and occupational risk assessment.
One of the problems with which the risk assessment
of nanoparticles is faced is the lack of data. This leads
to uncertainties in the characteristics of nanomaterials,
effects and exposure assessment, and testing consid-
erations (Grieger et al. 2009). Specifically, within food
safety, information is needed on the correct dose metric
to use, the toxicokinetics of nanoparticles, the food
products containing nanoparticles (Bouwmeester et al.
2009), the state of nanoparticles when manufactured
and when used, and the potential for exposure (Cock-
burn et al. 2012). In practice, this information is hard to
come by causing large uncertainty in the risk assess-
ment (Morgan 2005). Besides the lack of data, other
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sources of uncertainty can include disagreement
among literature sources, linguistic imprecision or
uncertainty about simplifications, or models used
(Morgan and Henrion 1990). Traditionally, this prob-
lem of uncertainty is solved deterministically using
worst-case scenarios. For example, a worst-case sce-
nario could make use of a highly sensitive individual, a
very high concentration of the specific chemical in the
product, or a very high consumption of the nano-
containing foods. This method, however, compromises
the transparency of the risk assessment (Jager et al.
2001) thereby leaving risk assessors groping in the dark
as to the various factors contributing to the risk
assessment result. Also the deterministic method does
not differentiate between variability and uncertainty.
There is neither quantification of uncertainty nor of
variability among individual persons regarding expo-
sure and sensitivity. An alternative is to incorporate
variabilities and uncertainties into the risk assessment
quantitatively using probabilistic methods. In a prob-
abilistic risk assessment, variabilities and uncertainties
can be quantified separately and the effect of all
separate sources can be seen on the risk assessment.
Within the REACH framework (REACH is a
legislation of the European Chemical Agency for the
Registration, Evaluation, Authorization and Restric-
tion of Chemicals) of tiered risk assessment (ECHA
2012), probabilistic risk assessment is a possible next
step when deterministic risk assessment methods
indicate a potential risk. Integrated probabilistic risk
assessment (IPRA) was developed as a framework in
which to conduct such a probabilistic risk assessment
(van der Voet and Slob 2007; Bosgra et al. 2009). It
was further developed and expanded to allow for more
than one adverse effect (van der Voet et al. 2009).
Although IPRA was developed for the risk assessment
of conventional chemicals (i.e., non-nanochemicals),
it is also a potential method for the risk assessment of
chemicals in nano-form.
Research on the use of probabilistic methods in the
risk assessment of nanoparticles in food is scarce.
A Scopus search (January 28, 2015) on the keywords
‘‘probabilistic,’’ ‘‘risk,’’ ‘‘food,’’ and ‘‘nano,’’ gave 0
results. Two less restrictive searches were also
performed: ‘‘probabilistic,’’ ‘‘risk,’’ and ‘‘food’’ (543
results) and ‘‘risk,’’ ‘‘food,’’ and ‘‘nano’’ (146 results).
Within this apparent research void, we present a case
study to illustrate the use of probabilistic risk assess-
ment in the area of nano and food.
In this paper, we expand the deterministic study of
Dekkers et al. (2011) on nanosilica in food into a fully
integrated probabilistic risk assessment. In doing so,
we will illustrate two points: how variability and
uncertainty in a risk assessment are quantified, and
how to determine which sources of uncertainty have
the biggest influence on the risk assessment results.
In the ‘‘Data and method’’ section, we will discuss
the data and methods used in our probabilistic risk
assessment. The ‘‘Results’’ section provides the
results. In the ‘‘Discussion’’ section, the results and
limitations are discussed, followed by a short conclu-
sion in the ‘‘Conclusion’’ section.
Our example is nanosilica-containing products
added to food. Food additives are generally assumed
safe for human consumption. E551 is a food additive
known as silicon dioxide or synthetic amorphous silica
(OECD 2004). It is mainly used as an anti-caking
agent in powders or powder-like products such as soup
powders, seasoning mix powders, and pancake mix.
The characterization and physicochemical properties
are extensively outlined in a JRC report (Rasmussen
2013) and summarized by van der Zande et al. (2014).
According to the Federation of European Specialty
Ingredient Industries, E551 does not contain nanopar-
ticles even though they are used in the production
process (ELC 2011). Dekkers et al. (2011), however,
found silica in nano-form in food products that contain
E551. They, therefore, performed a risk assessment of
nanosilica as found in E551, describing all steps of the
risk assessment process.
Data and method
The risk assessment paradigm consists of three main
parts: exposure assessment, hazard assessment (in-
cluding hazard identification and hazard characteriza-
tion), and risk characterization (FAO/WHO 1995).
The ratio of an estimate of tolerable exposure to an
exposure estimate is termed the margin of exposure
(MoE). This paradigm will be used when discussing
the various aspects of the deterministic and proba-
bilistic risk assessment. To provide the background
from which we develop the probabilistic risk assess-
ment, we first discuss the deterministic risk assessment
done by Dekkers et al. (2011). Next, the data used for
the risk assessment are described, and then the method
which makes use of the IPRA method for calculating
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the MoE in a probabilistic way (van der Voet and Slob
2007). Two main aspects include the use of distribu-
tions instead of worst-case values and the separation of
variability from uncertainty.
Background
A deterministic risk assessment of nanosilica in food
was done by Dekkers et al. (2011). By considering
labels of various brands of different powder products,
27 products were identified that contained E551.
These products were measured on their silica content.
In 12 of these products, the amount of nanosilica
(ranging from 0 to 33 % of the total silica content) was
also measured. In processed products, such as coffee
with coffee creamer, this percentage was higher. The
percentage nanosilica of total silica content in coffee
with coffee creamer was 43 % compared with 19 % in
raw coffee creamer. It was, therefore, suggested that
processing increases the amount of silica in nano-
form. Based on this hypothesis, a worst-case assump-
tion of 50 % nanosilica was used for the remaining 15
products for which the amount of nanosilica was not
measured. The consumption of the 27 products was
based on worst-case estimates (maximal consumption)
made by expert judgment. Combining the concentra-
tion with the consumption information, a worst-case
exposure of 1.8 mg/kg BW/day nanosilica was
obtained.
For the hazard characterization, Dekkers et al.
(2011) used a published toxicity study on mice (So
et al. 2008). This mouse study was a 10-week oral
toxicity study with one control group and one treat-
ment group. The treatment group was fed 1,500 mg/
kg BW/day nanosilica. This study showed potential
liver toxicity, which was seen in increased alanine
aminotransferase (ALT) levels and fatty liver patterns
after hematoxylin and eosin (H&E) staining (So et al.
2008). A lowest observed adverse effect level
(LOAEL) of 1,500 mg/kg BW/day nanosilica was
derived because an adverse effect was observed at the
tested dose level.
In the risk characterization, Dekkers et al. (2011)
estimated the ratio of the LOAEL to the estimated
exposure, which we term the MoE, alternatively
referred to as the margin of safety (MoS). A MoE less
than one occurs when exposure is greater than
LOAEL. The use of one as a threshold for safety is
not appropriate, however, because the MoE compares
human exposure with animal toxicity. Humans may or
may not be more sensitive to a substance than animals.
Traditionally, for conventional chemicals, an assess-
ment factor of 10 is applied to animal toxicity to
accommodate this difference (Lehman and Fitzhugh
1954). Besides animal to human extrapolation, we also
have to deal with variability in the human population
itself. A sick, young, or old human being will possibly
be more sensitive to a substance than the average-aged
healthy human being. This variation is usually also
represented by a factor of 10 (Lehman and Fitzhugh
1954). The two assessment factors result in a com-
bined assessment factor of 10 9 10 = 100. It is,
therefore, common within the risk assessment com-
munity to compare the MoE for conventional chem-
icals with the tolerance value of 100: a MoE greater
than 100 is deemed to be safe (Lehman and Fitzhugh
1954). In this context, the MoE (850) obtained by
Dekkers et al. (2011) would be high enough for
nanosilica to be judged safe. There are, however, some
doubts whether this is the case. First, the scientific
basis for a safety margin of 100 is unclear (ECETOC
1995). Second, whether this value is appropriate for
use in the context of nanoparticles is uncertain
(Dekkers et al. 2011).
There are more uncertainties in the risk assessment
of nanoparticles. Another source of uncertainty is the
appropriate dose metric to use. The classical dose
metric used in chemical risk assessment is mass per
unit of body weight. In nanoparticle risk assessment,
however, this might be different. It has been suggested
that for oral toxicity, particle number (N) per unit of
body weight might be a more appropriate dose metric
(Pasupuleti et al. 2012) and for inhalation toxicity,
surface area might be a more appropriate dose metric
(Maynard and Kuempel 2005). Dekkers et al. (2011)
provided the risk characterization using both these
dose metrics. To derive either of these dose metrics,
one needs the particle size. This derivation adds
uncertainty to the risk assessment because there is
uncertainty about the particle size. This uncertainty
results in uncertainty in the MoE. Instead of a single
MoE value (850), a range of possible MoE values was
obtained: 280 through 5,600 m2/kg BW/day and 31
through 250,000 N/kg BW/day (Dekkers et al. 2011).
Here we take note that the added uncertainty of the
dose metric results in a potential risk (31 is less than
100). Taking into account this source of uncertainty
and other possible uncertainties such as the correct
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assessment factor to use and the lack of toxicity data,
Dekkers et al. (2011) concluded that, even in the initial
case of 850, the MoE is probably not large enough to
allow for all the extrapolation steps and uncertainty.
This issue is the basis for the current paper. We argue
that probabilistic methods, in which uncertainty and
variability are quantified as far as possible, provide a
more transparent risk assessment. It decreases uncer-
tainty about whether a certain MoE is high enough and
also provides insight into which sources of uncertainty
contribute most to the final risk assessment.
Concentration data
Concentration data were obtained from the Dekkers
et al. (2011) study. Of the 27 products measured for total
silica content, 25 products had a positive total silica
concentration. Of these 25, 11 products were also
measured on nanosilica content (see Table 1). In the
deterministic study, the nanosilica concentration for the
14 products not measured on nanosilica content was
taken as 50 % of the total silica concentration. A recent
study, however, has pointed out that this percentage is
Table 1 Concentration of total silica and nanosilica in measured food products and linking to Dutch National Food Consumption
Survey (DNFCS) products





Corresponding product types from
DNFCS (percent of basic product in the
DNFCS product)
Sauce powder Mix for lasagna sauce 5.4 0.3 Sauce prepared from sauce powder (18 %)
Cheese sauce 6.6 Dishes containing sauce (9 %)
Meat seasoning Minced meat seasoning mix 2.6 0.2 Pure meat seasoning (100 %)
Dishes containing meat seasoning (3 %)
Cake mix Cake with icing 0.6 Pure cake flour (100 %)
Cakes containing flour (55 %)
Instant noodles Instant noodles tandoori 12.9 Noodle dishes (3 %)
Instant noodles chicken 5.8
Instant soup powder Instant asparagus soup 0.6 0.2 Soup prepared from instant soup powder
(6 %)Instant beef soup 0.6
Coffee creamers Coffee creamer (brand a) 5.1 1.0 Pure creamer (100 %)
Coffee creamer (brand b) 4.9 Drinks containing creamer (3 %)
Rubs Spicy pepper rub 1.1 \0.1 Pure bread crumbs (100 %)
Sweets sticky rub 6.0 0.4 Dishes containing bread crumbs (10 %)
Steak house rub 4.3 0.2
Roasted vegetable rub 4.9 0.6
Sea food rub 4.7 0.5
International seasoning mixes Burrito seasoning mix 7.1 0.3 Pure spice mix (100 %)
Taco seasoning mix 11.4 Dishes containing spice mix (10 %)
Guacamole seasoning mix 5.8 Dishes containing spice mix and a starch
(5 %)Nasi rames seasoning mix 6.2
Pancake mix Pancake mix 2.8 \0.1 Pure pancake flour (100 %)
Pancakes containing pancake flour (32 %)
Cappuccino creamer Cappuccino foam creamer 4.9 Drinks containing cappuccino creamer (3 %)
Soy shake Soy slim shake 3.4 Drinks prepared from soy shake (8 %)
Vitamin C tablets Vitamin C 1.5 Vitamin C tablets, pills and capsules
(100 %)
Multivitamin Junior Multivitamins junior (brand a) 13.7 Multivitamin junior or kid tablets, pills
and capsules (100 %)Multivitamins junior (brand b) 13.7
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variable after consumption of the food and can even
become as high as 100 % in the gastro-intestinal tract
(Peters et al. 2012). This makes the measured nanosilica
concentrations before consumption less relevant. We,
therefore, chose not to use the nanosilica measurements,
but rather the total silica measurements and model the
uncertain percentage of nanosilica with a distribution.
Details are explained in the ‘‘Method’’ section.
Some of the 25 silica-containing products repre-
sented the same basic product, e.g., two types of
instant soup powder. We identified 13 basic products
with 1–5 measured products per basic product (see
Table 1). The basic products are assumed to represent
all the powder food types which contain the food
additive E551.
Consumption data
The consumption data were obtained from the Dutch
National Food Consumption Survey (DNFCS) of
2007–2010. This survey was conducted by the
National Institute for Public Health and the Environ-
ment (RIVM) from 2007 to 2010 on the Dutch
population aged 7 through 69 years (van Rossum et al.
2011). It contains the consumption of 3819 respon-
dents on two non-consecutive 24-h dietary recalls.
Consumed products are identified by their NEVO code
(Nederlandse Voedingsmiddelentabel, Netherlands
Food Table) and classified into one of the EPIC-SOFT
food (sub-)groups (Voss et al. 1998). Using these (sub-
)groups, we identified products containing one or more
of the measured products, i.e., all products that contain
or have as ingredient a powdered product.
Linking concentration and consumption data
The basic products had to be linked with the consumed
products from the DNFCS. This linking was done by
identifying products in the DNFCS, which contain or
are produced from the basic products. The percentage
of the basic product in the DNFCS product was
determined as follows. By consulting food packaging
labels, the amount of powder ingredient to produce the
prepared product was determined. For complete meals
that contain the prepared product, a rough estimate
was made for the percentage of the meal that consists
of the prepared product.
Table 1 provides a list of the basic products,
corresponding measured products (with total silica
and nanosilica concentrations), and corresponding
product type from the DNFCS and food composition
percentages. For a detailed table listing specific
products from the DNFCS, the reader is referred to
Table S1 in Supplementary Material.
Dose–response data
In this paper, we use the toxicity study of van der
Zande et al. (2014) as a replacement for the So et al.
(2008) study used in the deterministic assessment
discussed in the ‘‘Background’’ section. Van der
Zande et al. (2014) performed a 28-day and a 84-day
oral toxicity study in rats. The 84-day oral toxicity
study showed increased liver fibrosis at high doses of
nanosilica. This was investigated by considering ten
slides of liver cells per rat. The occurrence and
severity of fibrosis were noted. In the 84-day oral
toxicity study, 15 rats were divided into one control
and two treatment groups. In treatment 1, 5 rats were
fed with synthetic amorphous silica (SAS) at an
intended dose of 2,500 mg/kg BW/day. In treatment
2, 5 rats were fed with pyrogenic NM-202 [the OECD
representative nanostructured silica for applications
related to food (van der Zande et al. 2014)] at an
intended dose of 1,000 mg/kg BW/day. After prepar-
ing the food, the realized concentration of silica in the
nano-sized range (5–200 nm) was measured. The
concentrations were 0 mg/kg BW/day for the control,
819 mg/kg BW/day for the SAS treatment, and
810 mg/kg BW/day for NM-202. We assumed the
two treatments to be two dosages of the same
substance because no or minor differences were found
between SAS and NM-202 in powdered form after
in vitro digestion and in intestinal solubility (van der
Zande et al. 2014). In this way, we have three dose
groups which we can use in a dose–response model.
This is described in the ‘‘Method’’ section. We
considered chronic risk assessment because liver
toxicity is a form of chronic toxicity. To this end, we
introduced a subchronic-to-chronic extrapolation fac-
tor for the toxicity study which is discussed in the
‘‘Quantifying variability in IPRA’’ section.
Method
We redid the deterministic study based on new toxicity
data and recent research on nanosilica fractions and
performed a probabilistic risk assessment using IPRA.
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In the deterministic study, we replaced the toxicity
data of So et al. (2008) with that of van der Zande et al.
(2014). Moreover, we replaced the 50 % nanosilica
percentage by 100 % as a new worst-case estimate.
IPRA uses a two-dimensional Monte Carlo scheme
to quantify uncertainty and variability distributions
separately in the risk assessment as illustrated in
Fig. 1. Details on the various aspects of the model are
discussed in the ‘‘Quantifying variability in IPRA’’
and ‘‘Quantifying uncertainty in IPRA’’ sections.
First, we describe the quantification of variability in
IPRA. Second, we describe how sources of uncertainty
for the nanosilica case are quantified.
Quantifying variability in IPRA
Following the basic three-component structure of risk
assessment, we discuss exposure assessment, hazard
assessment, and risk characterization as part of the
IPRA method (variability loop of Fig. 1).
Exposure is probabilistically expressed as the
individual-day exposure (IDEXP), which is the
nanosilica intake by an individual on 1 day. The




CONS  CONCk ð1Þ
with CONCk = F 9 Ck, where CONSk is the con-
sumption of product k (in g/kg BW), Ck is the
concentration of nanosilica in product k (in mg/kg),
and F is an optional factor that can be added to allow
for changes in concentration and/or specific sources of
uncertainty. IDEXP is then the individual exposure to
nanosilica in lg/kg BW. The IDEXP distribution is
obtained by calculating the IDEXP for each of the
person days for which consumption data are available.
This distribution represents variability in individual
human intake at the person-day level. Because we
consider chronic toxicity, we need long-term expo-
sure. For this, the person-day level intake (IDEXP)
distribution needs to be converted into a distribution of
individual long-term exposures (IEXP). This conver-
sion is done using the NCI model (Tooze et al. 2006),
also known as the logisticnormal-normal (LNN)
shrinkage model, as detailed in MCRA (2013).
The factor F, from now on referred to as the
nanofraction, is used to convert silica concentration to
nanosilica concentration. Due to the chronic nature of
the risk assessment, any variability in the nanofraction
will be averaged out over the long term. This means
that we are only interested in a nominal nanofraction
value and its uncertainty. We chose 50 % as a nominal
value for the percentage of nanosilica in silica, i.e.,
F = 0.5. This nominal value was multiplied with Ck in
Eq. (1) to produce a value for the nanosilica concen-
tration in the basic product as found in the consumed
product. The (large) uncertainty associated with F is
discussed in the ‘‘Quantifying uncertainty in IPRA’’
section.
The above describes the method when using the
dose metric, mg/kg BW/day. We, however, also
consider the dose metric N/kg BW/day. Consumed
nanosilica particles vary in diameter from 5 nm
through 200 nm (Dekkers et al. 2011; Peters et al.
2012). We assume that with each consumption
moment a representative sample of particle sizes is
consumed. Moreover, because we consider chronic
exposure, consumption moments are modeled over
time, averaging out any particle size effect. This
Fig. 1 A schematic
diagram of uncertainty and
variability loops in the two-
dimensional Monte Carlo




dose, MoE margin of
exposure)
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means that we are only interested in the median
particle size. Considering various studies, we assumed
a median particle size of 100 nm (van der Zande et al.
2014; Peters et al. 2012). This particle size is used to
calculate the number of particles per mass unit (see
Appendix for details). For each of the Monte Carlo
iterations, the number of particles per mass unit is
multiplied with the concentration, Ck of that iteration
to produce an exposure value of nanosilica in 1012 N/
kg BW/day. For convenience, we divided N by 1012,
because N is very large.
Hazard is expressed as the individual benchmark
dose (IBMD), which is the dose at which an individual
human experiences a predefined response to a sub-
stance (higher IBMD means lower hazard). Starting
from a BMDanimal obtained from a dose–response
modeling of data from an animal study, the IBMD is
calculated using the formula:
IBMD ¼ BMDanimal
EFchronic  EFinter  IEFintra
where EFchronic is the best estimate for an extrapola-
tion factor for subchronic-to-chronic extrapolation,
EFinter is an extrapolation factor for the interspecies
conversion (from the average animal to the average
human), and EFintra is an individual extrapolation
factor for the intraspecies variation (deviation from the
average human).
To obtain the BMDanimal, we modeled the dose–
response data using PROAST software (Slob 2002;
Slob and Cotton 2013). The effect which we used to
quantify the toxicity of nanosilica was the number of
positive fibrosis slides (out of 10) per rat. This effect
variable has a Binomial (10, p) distribution for each
rat, with p the probability of obtaining a positive
fibrosis slide for that rat. We modeled this probability
using seven different models: logistic, probit, log-
logistic, log-probit, weibull, gamma, and linearized
two stage (Barlow et al. 2009). All seven models
passed the goodness of fit test at a 5 % level of
significance. For each model, PROAST calculated a
BMD as the ED50, which is the only relevant statistic
from a dose–response curve on quantal data when the
variation around the ED50 does not represent true
inter-personal differences in response but only differ-
ences between laboratory animals and other measure-
ment errors (Slob et al. 2011, 2014). We also
calculated the Akaike information criterion (AIC)
for each model to determine the best model. From
Table 2, we see that the logistic model is the best
fitting model (i.e., lowest AIC), although the differ-
ences are small. From this model (Fig. 2), we obtained
the nominal BMDanimal of 1,160 mg/kg BW/day.
Model uncertainty is discussed in the next section.
The EFchronic accounts for the extrapolation from a
subchronic study to a chronic risk. Bokkers and Slob
(2005) studied such extrapolation based on the No-
observed-adverse-effect level (NOAEL) and the
benchmark approach. Not all studies which derive a
NOAEL, however, are suitable for benchmark mod-
eling. A more recent study, therefore, only used the
NOAEL approach (Batke et al. 2011). We, therefore,
used the data collected by Batke et al. (2011) to obtain
a median EFchronic of 1.475.
The EFinter accounts for the extrapolation from the
average animal to the average human. Interspecies
differences can be quantified in different ways, such as
extrapolation based on body weight, caloric demand,
or surface area (Vermeire et al. 1999). We used caloric
demand because it is a ‘‘biologically plausible and
data-based extrapolation method applicable to a wide
range of chemical substances’’ (Schneider et al. 2004)
Table 2 Dose-response
models with calculated log-
likelihood, AIC, and BMD
The null and full models are
added for comparison
NA not applicable
Model Number of parameters Log-likelihood AIC BMD
Null 2 -86.99 177.98 NA
Full 4 -80.45 168.9 NA
Linearized two-stage 4 -81.03 170.06 1300
Log-logistic 4 -81.02 170.04 1630
Weibull 4 -81.03 170.06 1330
Log-probit 4 -81.01 170.02 2650
Gamma 4 -81.02 170.04 1500
Logistic 3 -81.05 168.1 1160
Probit 3 -81.06 168.12 1450
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and is preferred above body weight scaling (Vermeire
et al. 1999). In allometric body weight scaling based
on caloric demand, the ratio of animal to human dose
is equal to the ratio of animal body weight to human
body weight raised to the power 0.75 (Vermeire et al.
1999). The EFinter based on the test species used, in our
case the rat, is obtained as




















We used the average body weight values as given
by Vermeire et al. (1999).
The IEFintra accounts for variability that exists
within the human population. We obtained the distri-
bution describing this variability using the method of
van der Voet et al. (2009) and the assumption that the
95th percentile sensitive person is 2–10 times more
sensitive than the average person (the range describing
uncertainty). The variability distribution is obtained as
a log-normal distribution with geometric mean equal
to one and a geometric standard deviation of 1.91 by
simultaneously accounting for the variability and the
uncertainty (see the ‘‘Quantifying uncertainty in
IPRA’’ section for further details).
To convert the dose metric of the IBMD, the
number of particles per mass unit as obtained previ-
ously was multiplied by the BMD of 1160 to obtain a
BMD in 1012 N/kg BW/day.
Finally, in the risk characterization part, we obtain
the distribution of the individual margin of exposure





A person is at risk when his/her exposure is greater
than his/her critical effect dose. Hence, an individual is
at risk when IMoE\1.
Quantifying uncertainty in IPRA
The method explained above is a probabilistic risk
assessment that accounts for variability that is present
in the human population (the variability, inner, loop of
Fig. 1). The next step is to account for uncertainty
(outer loop of Fig. 1). Again, we will consider
exposure and hazard separately.
For exposure, we need to consider the consumption
data, concentration data, and nanofraction. Sampling
uncertainty in consumption data was quantified by
bootstrapping the data at the level of individual persons
(500 iterations). We quantified the uncertainty in the
concentration data as far as possible by bootstrapping
the repeated measurements per basic product. Due to
the small number of measurements, however, this
probably underestimates the uncertainty. This limita-
tion is further discussed in the ‘‘Limitations’’ section.
Uncertainty in the nanofraction, F, was quantified
by a statistical distribution. As mentioned in
the ‘‘Concentration data’’ section, according to recent
research, the nanofraction, F, can be up to one
(100 %). This uncertainty about the nanofraction is
modeled by a logistic-normal distribution such that its
50th percentile (p50) is equal to 0.5 and its 95th
percentile (p95) is equal to 0.8. The logistic-normal
distribution was chosen because resulting values of
F are fractions bounded by 0\F\ 1. The probability
density function of a logistic-normal distribution is
given by
Fig. 2 Scatterplot of the dose–response data and fitted logistic
regression model for dosages of 0, 810, and 819 mg/kg BW/day
of nanosilica. The response is the probability of having a
positive (as defined by van der Zande et al. 2014) fibrosis slide
out of ten liver cell slides. The vertical dashed line indicates the
BMD. The circles indicate the mean response of each dose
group
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and Shen 1980). This distribution is denoted by
F*logisticnormal (l, r). Considering various distri-
butional shapes (see Fig. S1 in Supplementary Mate-
rial), we chose p95 = 0.8. This allows for at least 1 %
chance of values greater than 0.85 and at least 1 %
chance of values less than 0.15.
In each uncertainty iteration, an IEXP distribution
was calculated using inputs from the bootstrapped data
and uncertainty distributions. In this way, uncertainty
in the IEXP distribution was quantified.
For hazard, we need to consider uncertainty in the
BMDanimal, BMDchronic, EFinter, and IEFintra. We first
consider the BMDanimal. The BMDanimal is subject to
two main sources of uncertainty: limitations of the
dose–response data and model uncertainty. These
uncertainties were quantified by generating 100
datasets from each of the seven dose–response models
(see previous section) by the parametric bootstrap
method (Efron and Tibshirani 1994, p 53; Moerbeek
et al. 2004). From these, the BMDs were calculated,
and all 700 BMD values pooled into one set. This set
now includes uncertainties from the limitations of the
dose–response data and model uncertainty.
The uncertainty in the EFchronic. was quantified by a
log-normal distribution with expected value 1.80 and
standard deviation 1.52 (Batke et al. 2011).
From the ‘‘Quantifying variability in IPRA’’ sec-
tion, we calculated the nominal EFinter as four. This
value, however, is uncertain due to uncertainty about
potential toxicokinetic and toxicodynamic differences
between rats and humans. This uncertainty was
accounted for by deriving an uncertainty distribution
around EFinter. This derivation was done assuming the
99th percentile (p99) of the uncertainty distribution to
equal 10 (Slob and Pieters 1998). With four as the
geometric mean of the log-normal distribution, a
geometric standard deviation (1.48) for the uncertainty
distribution was obtained.
The IEFintra was assumed to contain both variability
and uncertainty. The variability distribution was
already given in the ‘‘Quantifying variability in
IPRA’’ section. The uncertainty in the geometric
standard deviation was quantified by a v2-distribution.
By setting the 2.5th percentile (p2.5) of the uncertainty
distribution equal to 2 and the 97.5 percentile (p97.5)
equal to 10, we are able to solve for the number of
degrees of freedom for the v2-distribution (van der
Voet et al. 2009).
By drawing an uncertainty value for each of the
BMDanimal, EFchronic, EFinter, and IEFintra, we calcu-
lated the IBMD. Repeating this process for 500
uncertainty iterations, we quantified the uncertainty
in the IBMD distribution. In the risk characterization,
independent draws from the uncertainty distributions
of the IEXP and the IBMD were combined into the
IMoE. In this way, uncertainty in the IMoE distribu-
tion was quantified from which the uncertainty
distribution of percentiles was obtained.
A simple graphical representation of both variabil-
ity and uncertainty of the IMoE can be given in the
form of a so-called IMoE bar graph. In an IMoE bar, a
box represents the variability distribution of the IMoE
between specified percentiles. These can be more or
less extreme percentiles (denoted by px for the xth
percentile), e.g., p0.1 and p99.9, p1 and p99, or p5 and
p95, depending on the level of protection required.
Whiskers are used to represent one-sided uncertainty
of these percentiles. We chose uncertainty limits such
that the left whisker represents the lower 5 % uncer-
tainty bound of the lower percentile and the right
whisker represents the upper 95 % uncertainty bound
of the upper percentile.
In addition to considering the effect of uncertainty
on the final risk assessment, it is important to identify
the extent to which sources of uncertainty contribute to
the total uncertainty present in a certain percentile of
interest. In IPRA, a probabilistic sensitivity analysis
was implemented to this effect, following the method
of van der Voet and Slob (2007). In short, seven
sources of uncertainty were considered, namely con-
sumption data, concentration data, nanofraction,
BMD, subchronic-to-chronic factor, interspecies fac-
tor, and intraspecies factor. These seven sources of
uncertainty result in a full 27 factorial design where
sampling from the uncertainty distribution for each
source is turned on and off. For each of the uncertainty
runs, 27 = 128 values are obtained for a given
percentile. In this way, 128 distributions are obtained
each of which is summarized by its variance. An
additive model is then fitted to the 128 variances.
When this model explains most of the variance, which
is usually the case, the coefficients of the main effects
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can indicate the contribution to the total variance. The
intercept term estimates uncertainty when all specified
seven sources of uncertainty are turned off and
represents uncertainty due to Monte Carlo calcula-
tions. Results are illustrated by means of a bar graph,
showing the percentage contribution of each source of
uncertainty.
Results
Figure 3 illustrates the IEXP and the IBMD distribu-
tions. The IEXP distribution is plotted as an exceedance
curve indicating the percentage of the population that
exceeds the exposure value on the x axis. The IEXP
curve starts at 1, indicating that all individuals have
some intake of nanosilica on the long run. This is due to
the nature of a chronic risk assessment. The amount of
overlap of the curves, which indicates the amount of
risk present and is related to the expected risk concept
of van Straalen (2002), appears small.
Figure 4 shows the results of the deterministic and
probabilistic risk assessments. Figure 4a–d provides
the deterministic MoE* values. Note that the deter-
ministic MoE values were divided by 100 to make them
comparable with the IPRA results (MoE* = MoE/
100). The values of MoE* calculated according to
Dekkers et al. (2011) are shown in Fig. 4a
(MoE* = 8.5) and Fig. 4b [MoE* = (0.31–2,500)],
whereas the values of MoE* calculated using the more
recent data as detailed in the ‘‘Method’’ section are
shown in Fig. 4c (MoE* = 2.94) and Fig. 4d
[MoE* = (0.11–8736.36)]. As discussed in the ‘‘Data
and method’’ section, the MoE* when using mg/
kg BW/day seems to be on the safe side. The lower
limits of the MoE* when using N/kg BW/day, how-
ever, give some cause for concern, because they are
less than one.
Figure 4e provides the probabilistic equivalent of
Fig. 4c and f that of Fig. 4d. IMoE bars are shown
below one another for p0.1–p99.9, p1–p99, and p5–p95.
Changing to a probabilistic approach including quan-
tified uncertainties does not lead to a higher perceived
risk, but rather tends to confirm that the results from the
deterministic study are worst case. Moreover, consid-
ering the uncertainty in particle size in a probabilistic
way has removed the concern of possible risk in the
deterministic case. Comparing Fig. 4e with 4f we see
that the different dose metrics give comparable results,
in contrast to the deterministic study. This difference
Fig. 3 The IEXP exceedance distribution (dashed curve) and
IBMD cumulative distribution (solid curve). The amount of
overlap of the curves indicates the amount of risk present
Fig. 4 Deterministic estimates MoE* = MoE/100 in mg/
kg BW/day (a, c) and in N/kg BW/day (b, d) according to
Dekkers et al. (2011) (a, b) and calculated with more recent data
(c, d) and IMoE bars illustrating the variability and uncertainty
distributions of the IMoE (e, f). The three boxes in each plot
represent IMoE distributions p0.1–p99.9, p1–p99, and p5–p95,
respectively, in mg/kg BW/day (e) and in N/kg BW/day (f). In
each box, the left whisker represents the lower 5 % uncertainty
bound of the lower percentile. The right whisker represents the
upper 95 % uncertainty bound of the upper percentile. The
dashed line indicates the median of the IMoE variability
distribution. Background coloring visualizes the transition from
high (red) to low risk (green). (Color figure online)
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between the deterministic study and our probabilistic
study is due to the fact that in the deterministic study, all
extremes in particle size were included in the calcula-
tions, while in the probabilistic study, consumers are
expected to be confronted with the whole distribution of
particle sizes, and therefore the particle size effect
cancels out in a chronic risk assessment.
For any choice of percentile of the IMoE distribu-
tion as the main indicator of a possible risk, it is
important to determine which sources of uncertainty
influence its value. As an example we will consider p1,
which is the left side of the middle box in the IMoE
bars in Fig. 4e and f. Figure 5 illustrates the contri-
bution of each source of uncertainty to the total
uncertainty of the p1 of the variability distribution of
the IMoE. The highest contributions to uncertainty of
p1 are the BMD, subchronic-to-chronic extrapolation
factor, and intraspecies factor, together accounting for
more than 80 % of the total uncertainty. A similar
pattern was obtained for p0.1 and p5 (not shown).
Discussion
One of the main features of IPRA is its ability to
quantify uncertainty and variability separately. This is
important because uncertainty is in principle
reducible, whereas variability is not. Uncertainty is
variation existing due to lack of data or information. In
this paper, the quantified uncertainty gave better
insight about whether the MoE obtained from the
deterministic study was large enough, given the large
uncertainties. We conclude that this is the case,
because our results indicate that even with the
uncertainty accounted for, we still end up on the safe
side. We cannot claim, however, that nanosilica in
food poses no risk, because certain uncertainties were
not quantified. This is discussed in the next subsection.
A feature of IPRA is the ability to study the
contribution of each source of uncertainty to the total
uncertainty. Knowledge of the most influential sources
of uncertainty can focus research to those areas in
order to decrease this uncertainty. We found that
uncertainty in the BMD, the subchronic-to-chronic
extrapolation factor, and the intraspecies factor con-
tributed most to the total uncertainty in the risk
assessment. Better dose–response data and more
research on dose–response model choice, sub-
chronic-to-chronic extrapolation, and on the variabil-
ity of human sensitivity would contribute much to
reducing the total uncertainty.
To decrease the uncertainty in the identified
sources, more research is needed to obtain more data
and better understanding of the data. More research in
the form of experiments can be expensive. An
additional method for obtaining data is expert elicita-
tion (Linkov et al. 2009). In such a method, experts are
asked to give their opinion on a certain variable. These
opinions can be used to obtain a first impression about
the uncertainty of that variable. This prior knowledge
can then be used to improve on the uncertainty
distributions which are fitted to the variables in a
probabilistic risk assessment, possibly in a Bayesian
context. One such an approach was illustrated in the
development of a multi-criteria decision model based
on expert judgment (Flari et al. 2011).
Limitations
Although we replaced many worst-case assumptions
where possible with statistical distributions, we still
made worst-case assumptions in some instances.
These include the decisions on which consumed
products contain the measured products and how
much of the measured product do they contain. The
description of products in the DNFCS and the
Fig. 5 A bar graph illustrating the relative contribution of each
source of uncertainty to the total uncertainty of the 1st
percentile (p1) of the IMoE distribution. The sources of
uncertainty are MC Monte Carlo uncertainty, Conc concentra-
tion uncertainty, Indiv consumption uncertainty, Fact nano
fraction (F) uncertainty, BMD BMDanimal uncertainty, Chronic
EFchronic uncertainty, Inter EFinter uncertainty, and Intra IEFintra
uncertainty. The variance explained by the additive model is
99.38 %
J Nanopart Res (2015) 17:251 Page 11 of 14 251
123
description of measured products are not detailed
enough to be able to make perfect matches. We,
therefore, assumed that all DNFCS products men-
tioned in Table S1 (see Supplementary Material) were
prepared using the basic product mentioned in the first
column. This assumption, of course, is a worst-case
assumption because DNFCS products could well have
been alternatively prepared or readymade. On the
other hand, it is possible that there are other food
products that also contain E551. In that case, we could
have underestimated exposure. For some food com-
position percentages, we assumed a worst-case sce-
nario. For instance, dishes containing sauce were
assumed to consist 50 % of sauce (e.g., minced meat
and white sauce).
The worst-case scenarios could have been replaced
by distributions describing the uncertainty. This could
be done by including more factors in Eq. (1) to
quantify the various uncertainties. These factors
would then represent uncertainty about whether we
included all products that contain E551, about the food
composition percentages and about the increase of
nanosilica in processed products.
Another concern could be the choice of 100 nm for
the median particle size. This choice was based on
studies (van der Zande et al. 2014; Peters et al. 2012)
in which particle sizes were measured. Due to the
limitations of the instrumentation and the difficulty in
measuring single particles in a large agglomeration
such as found in food products, a perfect estimate for
the median particle size was not possible. Further
research might increase our knowledge.
The contribution of the uncertainty of the nano
fraction is directly related to the uncertainty distribu-
tion chosen. The wider this distribution, the more
uncertainty we provide. Our choice was explained in
the ‘‘Quantifying uncertainty in IPRA’’ section, but
other choices are possible. Our results, therefore,
should be interpreted with this in mind. Choosing a
different value for p50 and p95 could have resulted in a
different situation, especially in the sensitivity anal-
ysis as illustrated in Fig. 5.
It should be noted that not all sources of uncertainty
were quantified. The uncertainty in silica concentration
was not well quantified because of the very limited
number of measurements (only 1–5 measurements per
food product). Another unquantified uncertainty is
whether the SAS and NM-202 used in the toxicity study
are comparable to the nanosilica found in food for
human consumption. A recent study questioned the use
of SAS for risk assessment of nanosilica in food
(Dekkers et al. 2013). Further unquantified uncertain-
ties could be related to limited toxicity data (only one
study with two dose groups), technical limitations in
measuring nanosilica concentrations in toxicity studies
and exposure assessment, and possible interaction with
other (nano) substances which could increase or
decrease the toxic effect of nanosilica. More research
is, therefore, necessary to find and reduce other
uncertainties that were not quantified. We suggest that
a probabilistic risk assessment be part of a larger risk
assessment framework in which possible other aspects
of risk or unquantifiable uncertainties are dealt with
qualitatively.
Finally, there are limitations to the application of
current risk assessment methods to nanoparticles. A
case study on nanosilver questioned whether the
REACH requirement of demonstrating ‘safe use’ of
a substance is currently possible for nanomaterials
(Pronk et al. 2009). To support a full risk assessment
for regulatory needs, further research is necessary in
generating high-quality data and developing method-
ologies (Peters 2011).
Conclusion
In this paper, we expanded the deterministic risk
assessment of Dekkers et al. (2011) into a fully
integrated probabilistic risk assessment. The overall
result of the probabilistic analysis of the risk of
nanosilica in food products shows, with 95 % confi-
dence, that at least 99 % of the Dutch population
would experience no risk. This conclusion is similar
for the two metrics chosen, in contrast to the results of
Dekkers et al. (2011) who indicated a much lower
possible MoE on the particles scale. We do need to
caution that this risk assessment is not 100 %
comprehensive and should only be seen as an
illustrative exercise. The results are not intended as
an authoritative risk assessment on nanosilica.
Approaching this risk assessment from a proba-
bilistic method, we obtained a more transparent picture
of risks and a better insight into the extent that
uncertainty plays in the risk assessment process. We,
therefore, conclude that in cases where deterministic
methods show possible risks in a lower-tier assessment
and different sources of variability and uncertainty are
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known to influence the results, probabilistic methods of
risk assessment are preferable.
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Appendix
In this section, we detail the calculations for
obtaining a different dose metric. To convert mg/
kg BW/day to number of particles, we use the
particle diameter and the density of nanosilica,
assuming that particles are solid spheres.




with r the radius of a particle in nm.
2. Calculate the mass of one particle (in mg):
mparticle ¼ mparticle  dnanosilica
with dnanosilica the density of nanosilica in mg/nm
3.
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